Menu
We are Arquer Diagnostics, a dynamic, female-led and UK-based company working at the cutting-edge of cancer diagnostics. It is our mission to transform how patients are diagnosed with cancer and then monitored throughout their treatment journey. We develop and commercialise non-invasive, highly accurate, cost-effective cancer biomarker tests. We believe no one should have to undergo unnecessary invasive and painful procedures
Nadia is an accomplished senior executive in the Life Sciences sector with experience across several therapeutic areas and spanning EMEA, Asia Pacific and North America. She has held senior positions at Alium Medical Limited, Allergan, Boston Scientific and Medtronic. Most recently Nadia served as the Partner & Managing Director Europe for Tefen Management Consulting. Nadia has a strong background in business management and product commercialisation.
Maddy is a seasoned CFO in the Life Science sector –both in public and private companies- with experience in fundraising, financial modelling, SME growth, M&A and IPO. Previous roles included MyHealthChecked plc, Ieso Digital Health Ltd, Psioxus Therapeutics Ltd, Lab21 Ltd, and Alliance Pharma plc. She is an FCCA and has a Post Graduate Diploma in Financial Strategy from Said Business School, Oxford.
Emma has over 20 years of experience in working in the Medical Devices industry including in vitro diagnostics (IVD) and the Pharmaceutical industry (private and public sector). In her career she was part of very successful IVD development and licencing projects in multiple companies (Gen-Probe/Hologic, Quotient Ltd. and LumiraDx) with Clinical, Regulatory and Quality responsibilities. Emma holds a degree in Biochemistry & Genetics and gained her PhD in protein degradation at the University of Newcastle.
Jacqui has a strong cancer research background with over 15 years’ experience. She has extensive experience in molecular biology, genetics and diagnostic tests having worked as a postdoctoral researcher at Newcastle University, the University of Sheffield and the Cancer Research UK Beatson Institute in Glasgow, one of Europe’s leading cancer research centres. Jacqui gained a PhD in Urological Oncology at the Northern Institute for Cancer Research, Newcastle University.
Nadia is an accomplished senior executive in the Life Sciences sector with experience across several therapeutic areas and spanning EMEA, Asia Pacific and North America. She has held senior positions at Alium Medical Limited, Allergan, Boston Scientific and Medtronic. Most recently Nadia served as the Partner & Managing Director Europe for Tefen Management Consulting. Nadia has a strong background in business management and product commercialisation.
Maddy is a seasoned CFO in the Life Science sector –both in public and private companies- with experience in fundraising, financial modelling, SME growth, M&A and IPO. Previous roles included MyHealthChecked plc, Ieso Digital Health Ltd, Psioxus Therapeutics Ltd, Lab21 Ltd, and Alliance Pharma plc. She is an FCCA and has a Post Graduate Diploma in Financial Strategy from Said Business School, Oxford.
David represents Longwall Ventures, a key investor in Arquer. He started his career as a graduate engineer in Carnaud Metalbox (now Crown Cork), working in a range of roles from R&D to production and project management. David spent much of his career living and working overseas in Spain, Argentina, Belgium and France. David studied for his MBA at Harvard Business School, after which he joined Z Corporation, an MIT licensee start-up. He spent several years growing the European and Asian businesses before entering the venture industry. David predominantly focuses on physical science and engineering investment opportunities.
NHS Urologists: To discuss how to get ADXBLADDER testing in a NHS Hospital, please contact ArquerDX directly on 0191 516 6765.
Arquer is interested in opportunities for in-licensing cancer biomarkers or technologies where there is a fit with our current platform and products.
Arquer Diagnostics’ assay platform is readily adaptable for the detection of other cancer biomarkers, so provides a rapid route to market based on proven technology.
If your business, university department, other scientific or medical organisation has cancer biomarkers or technologies that might be suitable licensing candidates, please get in touch.
Do you have a clinical trial or a sampling device that may be compatible with Arquer’s technology? If you are interested in collaborating with Arquer in the development of a cancer diagnostic, please get in touch.
Could you help Arquer design and produce innovative, non-invasive cancer tests for diagnosis and monitoring?
If you are interested in a career with Arquer Diagnostics, contact us today.
Email your CV/resumé to: info@arquerdx.com
